Combination therapy with antibody‐drug conjugate RC48 (disitamab vedotin) and zimberelimab (PD‐1 inhibitor) successfully controlled recurrent HER2‐positive breast cancer resistant to trastuzumab emtansine: A case report. This evidence concerns the gene ERBB2 and breast cancer.